PM
Prosight Management Portfolio holdings
AUM
$410M
This Quarter Return
+13.39%
1 Year Return
-14.96%
3 Year Return
+21.81%
5 Year Return
+1.17%
10 Year Return
–
AUM
$218M
AUM Growth
+$218M
(+13%)
Cap. Flow
+$5.04M
Cap. Flow
% of AUM
2.31%
Top 10 Holdings %
Top 10 Hldgs %
60.56%
Holding
45
New
9
Increased
9
Reduced
17
Closed
9
Top Buys
| 1 |
Bristol-Myers Squibb
BMY
|
$13.5M |
| 2 |
Cigna
CI
|
$10.4M |
| 3 |
NVRO
NEVRO CORP.
NVRO
|
$8.05M |
| 4 |
UroGen Pharma
URGN
|
$5.83M |
| 5 |
CLVS
Clovis Oncology, Inc.
CLVS
|
$4.7M |
Top Sells
| 1 |
AGN
Allergan plc
AGN
|
$8.21M |
| 2 |
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
|
$6.61M |
| 3 |
Galapagos
GLPG
|
$5.77M |
| 4 |
HNGR
Hanger Inc.
HNGR
|
$4.87M |
| 5 |
Viking Therapeutics
VKTX
|
$4.77M |
Sector Composition
| 1 | Healthcare | 89.78% |
| 2 | Technology | 3.18% |
| 3 | Industrials | 2.01% |
| 4 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Cigna
CI
$80.3B
| $22.2M | 9.71% | 138,000 +64,700 | +88% | +$10.4M |
|
|
HNGR
2
DELISTED
Hanger Inc.
HNGR
| $17.8M | 7.78% | 933,548 -255,851 | -22% | -$4.87M |
|
3
Zimmer Biomet
ZBH
$21B
| $15.8M | 6.9% | 123,500 +20,120 | +19% | +$2.57M |
|
|
RETA
4
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $15M | 6.57% | 175,700 -77,300 | -31% | -$6.61M |
|
|
5
Bristol-Myers Squibb
BMY
$96B
| $13.5M | 5.91% | +283,000 | New | +$13.5M |
|
|
ARNA
6
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $11.3M | 4.95% | 252,500 -25,150 | -9% | -$1.13M |
|
|
WCG
7
DELISTED
Wellcare Health Plans, Inc.
WCG
| $11M | 4.8% | 40,700 -9,300 | -19% | -$2.51M |
|
8
Iovance Biotherapeutics
IOVA
$807M
| $8.72M | 3.82% | 917,080 -145,420 | -14% | -$1.38M |
|
|
ALBO
9
DELISTED
Albireo Pharma, Inc. Common Stock
ALBO
| $8.69M | 3.8% | 269,836 -310 | -0.1% | -$9.99K |
|
|
NVRO
10
DELISTED
NEVRO CORP.
NVRO
| $8.05M | 3.52% | +128,765 | New | +$8.05M |
|
11
ASGN Inc
ASGN
$2.38B
| $6.93M | 3.03% | 109,116 +21,416 | +24% | +$1.36M |
|
12
Assembly Biosciences
ASMB
$190M
| $6.19M | 2.71% | 314,410 +38,469 | +14% | +$757K |
|
|
CLVS
13
DELISTED
Clovis Oncology, Inc.
CLVS
| $6.19M | 2.71% | 249,389 +189,289 | +315% | +$4.7M |
|
|
14
UroGen Pharma
URGN
$900M
| $5.83M | 2.55% | +157,862 | New | +$5.83M |
|
15
Aldeyra Therapeutics
ALDX
$351M
| $5.27M | 2.3% | 583,300 +178,837 | +44% | +$1.61M |
|
16
BioMarin Pharmaceuticals
BMRN
$11.2B
| $5.1M | 2.23% | 57,384 -45,616 | -44% | -$4.05M |
|
|
SBBP
17
DELISTED
Strongbridge Biopharma plc.
SBBP
| $4.65M | 2.03% | 933,876 -4,024 | -0.4% | -$20K |
|
|
WAGE
18
DELISTED
WageWorks, Inc.
WAGE
| $4.38M | 1.92% | +115,926 | New | +$4.38M |
|
|
SRRA
19
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
| $4.2M | 1.84% | 2,457,683 -96,260 | -4% | -$165K |
|
20
Centene
CNC
$14.3B
| $4.16M | 1.82% | 78,400 +53,400 | +214% | +$2.84M |
|
21
Tempest Therapeutics
TPST
$44M
| $4.06M | 1.78% | 270,762 +14,023 | +5% | +$210K |
|
22
Indaptus Therapeutics
INDP
$7.19M
| $3.98M | 1.74% | 542,919 -133,185 | -20% | -$976K |
|
23
Gyre Therapeutics
GYRE
$703M
| $3.93M | 1.72% | 484,200 +17,300 | +4% | +$140K |
|
24
AC Immune
ACIU
$205M
| $3.59M | 1.57% | +710,541 | New | +$3.59M |
|
|
TLGT
25
DELISTED
Teligent, Inc
TLGT
| $3.53M | 1.54% | 3,041,568 -506,039 | -14% | -$587K |
|